<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ NFX.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">NFX.L</div>
            <div class="company-name">Nuformix plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£6,223,761</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 434 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ WATCH</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #f59e0b;">60</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">45</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fef3c7; color: #92400e;">EARLY BUILD</span>
            </div>
            
            <div class="thesis-line">
                WATCH - EARLY_BUILD timing with 60/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üè≠</span>
                CrashDash Intelligence ‚Ä¢ Industrials
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#f59e0b 237.6deg, #e5e7eb 237.6deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #f59e0b;">66</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #f59e0b; margin-bottom: 12px;">HIGH PANIC</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü† Fear dominant - watch for reversal signs</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 40/40</div>
                            <div>üìâ Volume: 10/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 10/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #f59e0b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üü† Fear 66/100</span><span style="display: inline-block; background: #10b981; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üìä Building</span><span style="display: inline-block; background: #3b82f6; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üåü APEX 60</span>
                </div>
                
                <!-- Opportunity Flag -->
                <div style="margin-top: 20px; padding: 16px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 10px; color: white; font-weight: 700; font-size: 16px;">üéØ ‚ö†Ô∏è HIGH PANIC + Early timing = Potential accumulation phase</div>
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 136.8deg, #e5e7eb 136.8deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">38</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">üü¢ MILD COMPRESSION (Top 50% - WATCHLIST)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.8</strong> signals/week</div>
                                <div><strong>7</strong> RSI &lt; 20 events</div>
                                <div><strong>0</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+870%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #eab308;">18/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #eab308; height: 100%; width: 45.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.8 signals/week | 7 RSI<20 | üìä MODERATE COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Normal volume</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #ef4444;">15/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #ef4444; height: 100%; width: 100.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">BIG POPPER - Historical 5x+ (870%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 40/40 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üìà Historical upside: 870% proven capacity</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    ‚öñÔ∏è Mixed signals - Fear and facts balanced, wait for clarity
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Industrials)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book decline or cancellations</div><div>‚Ä¢ Margin compression (input costs)</div><div>‚Ä¢ Cyclical demand weakness</div>
                    </div>
                    <div style="margin-top: 12px; padding: 10px; background: #fef3c7; border-radius: 8px; font-size: 12px; color: #92400e; font-weight: 600;">üö® Active: Project delays or overruns</div>
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book growth or new contracts</div><div>‚Ä¢ Margin recovery (efficiency gains)</div><div>‚Ä¢ Cyclical upturn (capex recovery)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">NXP002 Update</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Director/PDMR Dealings</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Result of General Meeting</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Results for the period ended 30 September 2023</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Notice of AGM</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #f59e0b;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #f59e0b; font-size: 20px;">BUY</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    üéØ CrashHunter Signal: ‚ö†Ô∏è HIGH PANIC + Early timing = Potential accumulation phase
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (5/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üî¥</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">66/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚úÖ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">EARLY_BUILD</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚≠ê</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">60/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üéØ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">45/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üè≠</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">1 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        <div class="card" style="background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9;">
            <div class="card-title" style="color: #0369a1;">
                <span class="card-icon">ü§ñ</span>
                APEX Trader Brief v2
            </div>
            
            <!-- Bottom Line (Most Important) -->
            <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #0ea5e9;">
                <div style="font-size: 16px; font-weight: 700; color: #0369a1; margin-bottom: 10px;">üìù Bottom Line</div>
                <div style="font-size: 15px; line-height: 1.7; color: #1e293b;">
                    Bearish ‚Äì stay out until a clear revenue or product milestone emerges; the current story offers no compelling reason to buy.
                </div>
            </div>
            
            <!-- Company in 30 Seconds -->
            <div style="background: white; padding: 18px; border-radius: 10px; margin-bottom: 15px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #6366f1; margin-bottom: 12px; font-size: 15px;">üè¢ Company in 30 Seconds</div>
                <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                    <div style="margin-bottom: 8px;"><strong>What they do:</strong> NFX is a biotech firm focused on developing small‚Äëmolecule therapies for inflammatory conditions.</div>
                    <div style="margin-bottom: 8px;"><strong>Why they matter:</strong> Its lead candidate, NXP002, targets a large, under‚Äëtreated market of chronic pain sufferers, offering a potential new revenue stream for the sector.</div>
                    <div><strong>Current state:</strong> The company is still pre‚Äërevenue, operating on a modest cash runway and awaiting the first sales data from its clinical pipeline.</div>
                </div>
            </div>
            
            <!-- Buy vs Sell Decision -->
            <div style="background: white; padding: 18px; border-radius: 10px; margin-bottom: 15px; border-left: 4px solid #ef4444;">
                <div style="font-weight: 700; color: #ef4444; margin-bottom: 12px; font-size: 15px;">
                    üìâ 
                    Buy vs Sell ‚Äî Lean: BEARISH
                </div>
                <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                    <div style="margin-bottom: 10px;"><strong style="color: #10b981;">Bull Case:</strong> If NXP002 moves from clinical to commercial status and the company secures a first revenue stream, the upside could be significant for a speculative buyer.</div>
                    <div style="margin-bottom: 10px;"><strong style="color: #ef4444;">Bear Case:</strong> Without any sales data, active community interest, or a clear product launch, the price is likely to stay at 0.00p, making the position a pure gamble.</div>
                    <div><strong>Risk/Reward:</strong> Risk/reward is poor‚Äîhigh downside potential with only a slim chance of a meaningful upside.</div>
                </div>
            </div>
            
            <!-- What's Happening Now -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 15px; margin-bottom: 15px;">
                <div style="background: white; padding: 18px; border-radius: 10px; border-left: 4px solid #8b5cf6;">
                    <div style="font-weight: 700; color: #8b5cf6; margin-bottom: 12px; font-size: 15px;">üì∞ RNS Narrative</div>
                    <div style="padding: 6px 0; font-size: 14px; line-height: 1.6; color: #334155;">‚Ä¢ Listing and filing updates: the company has filed a series of routine AIM disclosures, including a change of auditor and an unaudited interim report.</div><div style="padding: 6px 0; font-size: 14px; line-height: 1.6; color: #334155;">‚Ä¢ Financial updates: the interim report and auditor change suggest the firm is keeping regulators in the loop, but no revenue figures were disclosed.</div><div style="padding: 6px 0; font-size: 14px; line-height: 1.6; color: #334155;">‚Ä¢ Product updates: NXP002‚Äôs inflammation study was highlighted, but the press release contains only a technical update, not a breakthrough announcement.</div><div style="padding: 6px 0; font-size: 14px; line-height: 1.6; color: #334155;">‚Ä¢ Capital raising: a ¬£70,000 subscription and warrants issue was announced, indicating a need for additional liquidity but also potential dilution for existing shareholders.</div>
                </div>
                
                <div style="background: white; padding: 18px; border-radius: 10px; border-left: 4px solid #ec4899;">
                    <div style="font-weight: 700; color: #ec4899; margin-bottom: 12px; font-size: 15px;">üí¨ Crowd Tape</div>
                    <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                        <div style="margin-bottom: 8px;"><strong>Theme:</strong> The community remains largely silent, with no active chatter to indicate a consensus.</div>
                        <div style="margin-bottom: 8px;"><strong style="color: #10b981;">Bulls:</strong> Bulls point to the product update and the small capital raise as early signs that the company is moving toward a commercial launch.</div>
                        <div style="margin-bottom: 8px;"><strong style="color: #ef4444;">Bears:</strong> Bears argue that the lack of sales data, flat social sentiment, and a 0.00p price make the story unconvincing.</div>
                        <div><strong>Shift:</strong> There has been no visible shift; sentiment remains muted since the last filing.</div>
                    </div>
                </div>
            </div>
            
            <!-- Attention Check -->
            <div style="background: white; padding: 18px; border-radius: 10px; margin-bottom: 15px; border-left: 4px solid #f59e0b;">
                <div style="font-weight: 700; color: #f59e0b; margin-bottom: 12px; font-size: 15px;">üëÄ Attention Check</div>
                <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                    Google trends are flat and social volume is zero, confirming that the story has lost any external oxygen and is not generating public interest.
                </div>
            </div>
            
            <!-- What to Expect Next -->
            <div style="background: white; padding: 18px; border-radius: 10px; margin-bottom: 15px; border-left: 4px solid #14b8a6;">
                <div style="font-weight: 700; color: #14b8a6; margin-bottom: 12px; font-size: 15px;">üîÆ What to Expect Next</div>
                <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                    <div style="margin-bottom: 10px;"><strong>Catalysts:</strong></div>
                    <div style="padding: 4px 0; padding-left: 15px;">‚Ä¢ July interim report ‚Äì the next filing could reveal early sales or a new partnership, which would be a decisive move for the bull case.</div><div style="padding: 4px 0; padding-left: 15px;">‚Ä¢ August capital raise completion ‚Äì if the subscription closes, the company will have additional cash but may face dilution, a key watchpoint.</div>
                    <div style="margin-top: 10px;"><strong>Watch for:</strong> Look for any revenue print, a product launch announcement, or director changes that might signal a shift in strategy.</div>
                    <div style="margin-top: 8px;"><strong>Timing:</strong> APEX marks the situation as early; the market has not yet priced in a catalyst, so entry is risky and timing is uncertain.</div>
                </div>
            </div>
            
            <!-- Playbook -->
            <div style="background: white; padding: 18px; border-radius: 10px; border-left: 4px solid #0ea5e9;">
                <div style="font-weight: 700; color: #0ea5e9; margin-bottom: 12px; font-size: 15px;">üìã Playbook</div>
                <div style="font-size: 14px; line-height: 1.6; color: #334155;">
                    <div style="margin-bottom: 10px;"><strong style="color: #10b981;">If Bullish:</strong> Not advisable to take a position at this stage; the story lacks traction and any upside is speculative.</div>
                    <div style="margin-bottom: 10px;"><strong style="color: #f59e0b;">If Watching:</strong> Hold off until the July interim report or a clear product announcement; then consider a small entry on a dip if the price moves above the current 0.00p level.</div>
                    <div><strong style="color: #ef4444;">If Passing:</strong> Stay out for now‚Äîno catalyst, no buzz, and the risk of a flat or negative move outweighs any potential upside.</div>
                </div>
            </div>
        </div>

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 60/100 indicates strong opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: EARLY_BUILD</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 3 rallies, 870% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 45/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 8/20 ‚Ä¢ Score: 10/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 88.6% from peak ‚Ä¢ Score: 18/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Above average volume</strong><br><small>1.9x average ‚Ä¢ Score: 6/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Solid track record</strong><br><small>3 previous rallies ‚Ä¢ Score: 10/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Monster potential</strong><br><small>Historical best: +870% ‚Ä¢ Score: 16/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">460%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">870%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.5x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Historically strong runner - massive upside when it moves</span>
                    <span class="tag" style="background: #10b981; color: white;">üî• High Conviction</span>
                </div>
                <div style="font-size: 12px; color: #666;">best run=870% ‚Ä¢ rally history=3.0</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Early stage positioning offers best R:R if catalysts appear</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">timing=EARLY BUILD ‚Ä¢ current return=460.0%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2024-11-08</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Watch / Starter</div>
                    <div style="font-size: 14px; opacity: 0.9;">Wait for base + catalyst confirmation; starter position only</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0-1% until CONFIRMED</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Invalidation = breaks recent lows / dilution / suspension</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out 25% at +15%, 25% at +50%, runner above</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 60/100 APEX score. Historical data shows 3 rallies averaging 870% upside. Current position: +460.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Strong historical rally behavior (870% best run)</div><div style="padding: 8px 0;">‚Ä¢ Early regime often offers best risk/reward</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Early accumulation phase. Watch for confirmation before committing size.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 45/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">NXP002 Update</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9th Apr 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Advisory Limited</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
9 Apr 2025 07:00
RNS Number : 1997E
Nuformix PLC
09 April 2025
9 April 2025
Nuformix plc
("Nuformix" or the "Company")
NXP002 Update
Positive results from analysis of lung tissue from IPF and autoimmune ILD patients
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurp
osing, is pleased to announce results following the re-analysis of data from previous studies of NXP002 in a precision-cut lung slice ("PCLS") disease model using tissue explanted from lung-transplant receiving patients with idiopathic pulmonary fibrosis ("IPF") and autoimmune-related interstitial lung disease ("ILD").
The data re-analysis undertaken was an outcome of on-going discussions with potential licensing and development partners for NXP002. In addition to patients with IPF and progressive pulmonary fibrosis ("PPF"), patients suffering from autoimmune ILDs (e.g. rheumatoid arthritis or systemic scleroderma) also have a high-mortality progressive fibrotic disease course which is not currently adequately treated.
In addition to lung tissue from seven IPF patients, NXP002 has been studied in tissue from an autoimmune ILD explanted lung (in this case from a patient diagnosed with non-specific interstitial pneumonia or NSIP).
This data
was revisited to compare key biomarker changes in tissue in response to NXP002 treatment using an 'area under the curve' (AUC) based approach, considering total biomarker expression during the treatment period.
These new results are summarised as follows:
¬∑
A clear dose response to NXP002 was observed
across both extra cellular matrix ("ECM") biomarkers and pro-fibrotic mediators suggesting NXP002's activity in additional pathways to standards of care;
¬∑
A consistent and significant effect of NXP002 was observed alone and in combination with
standards of care
across both biomarker types in all donors;
¬∑
When the Col1A1 gene was found to be overexpressed in tissue, representing active fibrotic disease and tissue turner, NXP002 consistently attenuates it's expression. When Col1A1 is not overexpressed Col1A1 is maintained, which may point towards NXP002's role in ECM homeostasis and supporting healthy tissue repair and regeneration, consistent with the evidence base describing positive results from clinical studies of tranilast in a range of fibrotic diseases; and
¬∑
The autoimmune-ILD donor studied also showed a significant response across both biomarker types alongside the seven IPF donors confirming that NXP002's activity translates well to autoimmune-derived ILDs.
Dr Dan Gooding, Executive Director, Nuformix, said:
"The PCLS lung tissue model has become the gold-standard disease model thanks to various close-to-patient benefits. We believe the dataset we have generated,
in what we believe is one of the largest IPF patient tissue sample sets studied, gives us great confidence in NXP002. In what is a highly variable and heterogenous disease, to see such consistent activity across all donors towards pro-fibrotic mediators in both IPF and autoimmune ILD is impressive. The emergence of data supporting additional activity towards Col1A1 overexpression is exciting because this profile would be in contrast to high-potency, single target therapeutics, whose activity may negatively impact healthy tissue repair processes, leading to increased risk in long term use as observed in numerous recent IPF clinical studies
. For patients with ILD's of an autoimmune origin, g
iven such patients' background systemic therapies, an inhaled approach towards treatment would be highly advantageous in both development and treatment. We are excited by the results and continue discussions with potential partners, who also see advantages in NXP002 in terms of therapeutic optionality and future product positioning. I look forward to providing further updates in due course."
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director
Via IFC Advisory
CMC Markets
Douglas Crippen
+44 (0) 20 3003 8632
IFC Advisory Limited
Tim Metcalfe
Zach Cohen
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
UPDQVLFBEZLXBBF
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üèõÔ∏è</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Director/PDMR Dealings</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">HOLDINGS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">5th Nov 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">2:25 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">European Union</td>
                    </tr>
                    
                        <tr style="border-bottom: 1px solid #e2e8f0;">
                            <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">ACTION:</td>
                            <td style="padding: 8px; font-weight: 600; font-size: 12px; color: #3b82f6;">PURCHASE</td>
                        </tr>
                        
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">1.57%, 1.57%, 3.49%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
5 Nov 2024 14:25
RNS Number : 0442L
Nuformix PLC
05 November 2024
5 November 2024
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Director/PDMR Dealings
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurp
osing, announces further to the completion of the Placing and
Subscription to raise gross proceeds of ¬£300,000, as announced on 20 September 2024, and Admission of the New Ordinary Shares today, further details of the Directors' participation in the Fundarise.
Each of the Company's Directors have subscribed for the following New Ordinary Shares at the Issue Price:
Name
Position
Ordinary shares subscribed for
% held of enlarged share capital on Admission
Julian Gilbert
Non-Executive Chairman
22,000,000
1.57%
Maddy Kennedy
Non-Executive Director
22,000,000
1.57%
Dan Gooding
Executive Director
12,000,000
3.49%
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 and as modified by or under the European Union (Withdrawal) Act 2018 or other domestic law, provides further detail.
Terms used in this announcement shall, unless the context otherwise requires, be as deÔ¨Åned in the Prospectus published by the Company on 16 October 2024.
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director
Via IFC Advisory
CMC Markets
Douglas Crippen
+44 (0) 20 3003 8632
IFC Advisory Limited
Tim Metcalfe
Zach Cohen
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Julian Gilbert
2
Reason for the notification
a)
Position/status
Non-Executive Chairman
b)
Initial notification/ Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Nuformix plc
b)
LEI
2138003XG3H3I2J3BJ24
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of nominal value 0.05 pence
GB00BYW79Y38
b)
Nature of the transaction
Purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s) Volume(s)
0.05 pence
22,000,000
d)
Aggregated information
-¬†Aggregated volume
-¬†Price
22,000,000
¬£11,000
e)
Date of the transaction
5 November 2024
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Maddy Kennedy
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification/ Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Nuformix plc
b)
LEI
2138003XG3H3I2J3BJ24
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of nominal value 0.05 pence
GB00BYW79Y38
b)
Nature of the transaction
Purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s) Volume(s)
0.05 pence
22,000,000
d)
Aggregated information
-¬†Aggregated volume
-¬†Price
22,000,000
¬£11,000
e)
Date of the transaction
5 November 2024
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Dan Gooding
2
Reason for the notification
a)
Position/status
Executive Director
b)
Initial notification/ Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Nuformix plc
b)
LEI
2138003XG3H3I2J3BJ24
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of nominal value 0.05 pence
GB00BYW79Y38
b)
Nature of the transaction
Purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s) Volume(s)
0.05 pence
12,000,000
d)
Aggregated information
-¬†Aggregated volume
-¬†Price
12,000,000
¬£6,000
e)
Date of the transaction
5 November 2024
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
DSHFLFFSLSLEIIS
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Result of General Meeting</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4th Nov 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">10:17 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Privacy Policy</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">98.00%, 2.00%, 97.99%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
4 Nov 2024 10:17
RNS Number : 8241K
Nuformix PLC
04 November 2024
4 November
2024
Nuformix plc
("Nuformix" or the "Company")
Result of General Meeting
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurp
osing, announces that at the General Meeting of the Company held earlier today all resolutions put to shareholders were duly passed and approved by way of a show of hands. The proxies received ahead of the General Meeting, are reported below:
Resolution
Ordinary/ Special
For
Against
Total votes cast
No. of votes
%
No. of votes
%
1
Subdivision of the ordinary shares
Ordinary
164,225,020
98.00%
3,356,013
2.00%
167,581,033
2
To authorise the directors to allot shares
Ordinary
163,856,186
97.99%
3,361,741
2.01%
167,217,927
3
To authorise the directors to disapply pre-emption rights
Special
163,856,186
98.04%
3,273,557
1.96%
167,129,743
4
Amendment of the Company's Articles of Association
Special
163,856,186
98.04%
3,273,557
1.96%
167,129,743
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
Full details of the Resolutions are contained in the Notice of General Meeting which is available, appended to the Prospectus, on the Company's website at:
https://nuformix.com/document-center/
Following the passing of the Resolutions at the General Meeting, the expected timetable of events remains the same as documented in the Prospectus and is as follows:
2024
Record Date for the Capital Reorganisation
6.00 p.m. on 4 November
Admission of New Ordinary Shares effective and commencement of dealing
8.00 a.m. on 5 November
Expected date for CREST accounts to be credited
5 November
Despatch of definitive certificates (where applicable) expected by no later than
11 November
Admission and Total Voting Rights
An application has been made to the London Stock Exchange for the
600,000,000
New Ordinary Shares, to be issued pursuant to the
conditional ¬£300,000 fundraise announced on 20 September 2024,
to be admitted to the equity shares (transition) category of the Financial Conduct Authority's Official List and to trading on the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission
and unconditional dealings in the New Ordinary Shares will commence on the London Stock Exchange at 8.00 a.m. on 5 November 2024.
Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 1,419,309,368, each with one voting right. The Company does not hold any rights in treasury. The total voting rights figure is therefore 1,419,309,368 and can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Terms used in this announcement shall, unless the context otherwise requires, be as deÔ¨Åned in the Prospectus published by the Company on 16 October 2024.
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director
Via IFC Advisory
CMC Markets
Douglas Crippen
+44 (0) 20 3003 8632
IFC Advisory Limited
Tim Metcalfe
Zach Cohen
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
ROMMZMGMGDVGDZM
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Results for the period ended 30 September 2023</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">POSITIVE RESULTS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Positive development - monitor for follow-through in share price.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">3rd Jan 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Period Ended</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">80%, 90%, 100%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
3 Jan 2024 07:00
RNS Number : 4386Y
Nuformix PLC
03 January 2024
3 January 2024
Nuformix plc
("Nuformix", the "Company" or the "Group")
Annual Results for the period ended 30 September 2023
Nuformix plc (LSE: NFX),
a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,
announces its audited results for the eighteen months ended 30 September 2023 following the change in the Company's accounting reference date from 31 March to 30 September.
Non-Executive Directors' Statement
Introduction
The key priority for the directors continues to be to focus on the Company's early-stage pipeline of preclinical assets and ensure strength in the areas of drug development, business development and financial control within the Group. We operate a lean structure with the limited Board and bring in specialists and consultants, experts in their field, to support the business as required.
Pipeline
Nuformix has an early-stage pipeline of preclinical assets in development to address the high unmet medical need in fibrosis and oncology. We target solutions using our expertise to develop and file patent applications on novel crystalline forms of existing, marketed drugs, that have improved physical properties, with the aim of developing novel products in new indications to create attractive commercial opportunities. Importantly, the commercial opportunity is optimised when the repurposed product is differentiated from the original marketed drug by way of either dose, route of administration or presentation.
Drug repurposing is a well-known and successful strategy for enhancing the therapeutic and commercial value of marketed drugs, and their development typically brings a greater probability of success compared to developing newly discovered drugs, due to the existing data that has been generated on the marketed drug. This existence of data may also result in lower overall development costs and shorter development timelines.
The Group's business model is to take these assets to key value inflection points before partnering or licensing. We conduct our R&D activities through out-sourcing, to enable us to access the different types of expertise that are needed for drug R&D and to minimise our operational costs. We have a strong network of external contractors, with whom we have had relationships over many years.
NXP002 (novel proprietary form of tranilast) - Idiopathic Pulmonary Fibrosis ("IPF")
NXP002 is the Group's preclinical lead asset and a potential novel inhaled treatment for IPF and possibly other fibrosing interstitial lung diseases ("ILDs"). It is a proprietary, new form of the drug tranilast, which allows the drug to be delivered in an inhaled formulation.
IPF is a devastating lung disease associated with a higher mortality rate than many cancers. Thus, IPF represents a high unmet medical need such that the requirement for improved treatment options represents a significant commercial opportunity. IPF is classified as a rare disease and presents a global commercial market that is forecast to grow to US$8.8bn by 2027. Sales of standard-of-care therapies OFEV and Esbriet (now off patent) achieved US$3.5bn and US$0.8bn respectively in 2022.
Tranilast has a long history of safe use as an oral drug for asthma, keloids and hypertrophic scarring, but there is growing evidence that supports its potential use in other fibrotic conditions, including IPF. NXP002 is differentiated as it is a patent protected new form of tranilast that has been enabled for formulation and delivery direct to the lungs by inhalation, a new route of administration for this drug. The inhalation route is a well-known strategy for treatment of lung diseases to yield greater efficacy and reduce systemic side-effects compared to oral treatment. Discontinuation rates for standard-of-care IPF therapies can be as high as 80% in certain patient groups due to their debilitating systemic side-effects.
Effective inhalation therapies offer the potential to overcome these limitations of oral therapies. Nuformix owns granted patents protecting new forms of tranilast, in addition to a recently filed patent protecting its use with SoC in IPF, with patent prosecution progressing in major pharmaceutical territories.
As a potential treatment for IPF, which is a rare disease, NXP002 is a likely candidate for Orphan Drug Designation, which could provide additional product protection against potential competitors. The positioning of NXP002 as an inhaled treatment for IPF could be either as added to Standards of Care (SoCs) or administered as a monotherapy
for patients non-responsive to SoCs and those declining these therapies due to side effects which impact quality of life.
The preclinical inhalation strategy,
initiated
by the Company has significantly progressed NXP002 demonstrating:
¬∑
it can be delivered
in-vivo
by a range of nebulisers at the optimum particle size for delivery to the deep lung;
¬∑
very high doses appear to be well-tolerated; and
¬∑
an
in-vivo
inhalation dose response was observed for inflammatory and fibrotic biomarkers that is consistent with all
ex-vivo
human IPF tissue studies to date.
The Company conducted
studies in a new iteration of a 3D human IPF lung tissue using a disease and species relevant model that has been
advanced to significantly reduce output variability
.
The results from these studies
of NXP002 alone and in combination with current SoC, can be summarised as follows:
¬∑
NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events;
¬∑
N
XP002 alone delivers a strong, consistent anti-fibrotic and anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis and inflammatio
¬∑
both high and low concentrations of NXP002 show an additive anti-fibrotic and anti-inflammatory effect to SoC;
¬∑
in particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other preclinical models to date; an
d
¬∑
the clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy. This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic and anti-inflammatory response.
As announced on 18 May 2023,
following success in suppressing biomarkers of fibrotic disease progression in
human IPF lung tissue
, the same samples were analysed to assess additional mechanistic and anti-inflammatory benefits on top of SoC's
and the results are summarised as follows:
¬∑
NXP002
alone delivers a strong, consistent anti-inflammatory effect as demonstrated by suppression of the release of inflammatory cytokines by over 90% for all cytokines studied; and
¬∑
the results further suggests that NXP002 will provide additional efficacy in combination with SoC's, even in patients responding to SoC therapy alone.
Nuformix has developed a Target Product Profile ("TPP") that is consistent with twice daily inhalation administration.
To assess NXP002's duration of action in relation to the TTP, the Company initiated work in an exploratory model in healthy human lung tissue. The model also bridges the Company's successful preclinical work across a variety of LPS-challenge studies.
The results are summarised as follows:
¬∑
NXP002 suppresses the release of inflammatory cytokines by healthy human lung tissue following LPS challenge; and
¬∑
a strong anti-inflammatory effect remains at 12 hours post drug dosing demonstrated by continued suppression of the release of inflammatory cytokines following LPS challenge, confirming NXP002 has a suitable duration of action to support its TTP of twice daily dosing.
Overall, the results further strengthen NXP002's potential for development as a new inhaled treatment for IPF either in addition to existing therapies or as a monotherapy.
The Board continues to be encouraged by the progress of the studies and the positive data generated to date, in particular the recent duration of action study results and is focused on next steps which include:
¬∑
expansion of the current studies to include further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations; and
¬∑
formally commencing the NXP002 partnering process.
Post-period end on 23 October 2023, the Company announced that it was issued with an Official Decision to Grant Notice of Allowance for
Japanese National Phase Patent Application No.
2020-555115
entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".
This patent, which has already been granted in the US, describes proprietary new forms of the drug tranilast being progressed by the Company as a potential novel IPF treatment. These proprietary drug forms uniquely enable delivery via an inhaled nebulised formulation.
NXP004 (novel forms of olaparib) - Oncology
The Group discovered novel forms of olaparib, a drug currently marketed by AstraZeneca, as Lynparza¬Æ. Lynparza¬Æ was first approved in December 2014 for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation. Since then, it has secured similar approvals in breast, pancreatic and prostate cancers with further trials on-going. These approvals have propelled Lynparza¬Æ sales to US$2.6bn in 2022 with industry analysts forecasting annual sales of US$9.7bn by 2028.
The Group has filed two patent applications on its novel forms of olaparib with the potential for patent life to 2040/2041.
The Company demonstrated enhanced performance of NXP004 cocrystals compared to olaparib. Subsequently, further preformulation studies allowed the Company to identify lead cocrystals to be progressed for further development.
Results from
in vitro
dissolution studies demonstrated that the two lead NXP004 cocrystals out-performed Lynparza
¬Æ
, both in terms of rate and extent of dissolution and release of olaparib.
Enhancement of dissolution in the currently marketed formulation of Lynparza
¬Æ
resulted in improved bioavailability versus the initial marketed product. Therefore, the NXP004 programme may offer potential to further increase olaparib bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.
These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products.
The Company will now consider the design and execution of
suitable preclinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of olaparib. Securing these data will enable commencement of discussions with
potential commercialisation partners.
This work will direct and support future out-licensing discussions for NXP004.
NXP001 (new form of aprepitant) - Oncology
NXP001 is a proprietary new form of the drug aprepitant that is currently marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting) exclusively licensed to Oxilio for oncology indications.
On 18 September 2023, the Company announced that Oxilio had acquired
ownership of its NXP001 patent estate
for which
Nuformix
received new immediate and near-term undisclosed milestone payments
, whilst retaining further development milestones and royalties capped at ¬£2 million per year.
Fundraising
On 13 April 2023, the Company completed a subscription to raise gross proceeds of ¬£70,000 through a subscription for 35,000,000 new ordinary shares of 0.1 pence each in the capital of the Company (the "New Ordinary Shares") at a price of 0.20 pence per share (the "Subscription"). The Subscription was undertaken with a single UK-based FCA regulated institutional investor. The New Ordinary Shares represented approximately 4.7 per cent. of the Company's enlarged issued share capital.
In addition, the participant in the Subscription was issued with one warrant for every one New Ordinary Share subscribed for with an exercise price of 0.25 pence per warrant. These warrants are exercisable for two years from 21 April 2023 ("Warrants"). If the Warrants are exercised in full, it would result in the issue of an additional 35,000,000 new ordinary shares raising a further ¬£87,500 for the progression of the Company's business activities. The New Ordinary Shares and Warrants were issued pursuant to the Company's existing share issuance authorities.
The net proceeds of the Subscription are being used by the Company primarily to further advance its NXP002 programme for the inhaled treatment of IPF.
Lanstead Subscription and Sharing Agreements
During the period the Company received proceeds from
the Company's subscription and associated sharing arrangements with
Lanstead Capital Investors L.P. ("Lanstead"), as announced on
14 December 2021
,
17 January 2022 and 12 April 2022. The sharing agreements ended in October 2023, concluding this arrangement and the Company is due no further funds from Lanstead.
Business Development
During the period the Company has switched its focus to business development activities to explore partnering opportunities for both its NXP002 and NXP004 programmes, attending both the European Respiratory Conference in Milan and the IPF Summit in Boston. Those partnering activities are ongoing.
Summary and Outlook
The strategy of the Group is to continue to optimise value from its existing assets while maintaining tight control of costs. The proceeds from the Lanstead Sharing Agreements, the April 2023 fundraise proceeds and the milestone payment received from Oxilio in September 2023 and post-period in December 2023 have enabled the Group to continue to advance and exploit the current assets within the portfolio through selective additional R&D and business development activities as set out above. The Group is conducting business development/licensing activities for all its assets using a structured and data-driven approach, with the goal of seeking global licensing deals. Our focus and emphasis is to progress our NXP002 and NXP004 programmes where required to complete licensing transactions and achieve value creation to generate a return for shareholders.
We would like to thank all stakeholders and in particular our shareholders for their continued support and we look forward to the remainder of the year and beyond with confidence that significant value can be realised from our portfolio of assets over time.
Julian Gilbert Madeleine Kennedy
Non-Executive Chairman Non-Executive Director
2 January 2024 2 January 2024
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director
Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)
+44 (0) 20 3650 3650
Bob Pountney (Corporate Broking)
+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe
Zach Cohen
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
Strategic Report
Review of the Business
A review of the period of these accounts is given in the Non-Executive Directors' Statement above.
Risks and uncertainties
The Group's risk management policy is regularly reviewed and updated in line with the changing needs of the business. Risk is inherent in all business. Set out below are certain risk factors which could have an impact on the Group's long-term performance and mitigating factors adopted to alleviate these risks. This does not purport to be an exhaustive list of the risks affecting the Group.
The primary risks identi?ed by the Board are:
Strategic risks
¬∑
Funding the business
The biotechnology and pharmaceutical industries are very competitive, with many major players having substantial R&D departments with greater resources and ?nancial support. The Group aims to execute licensing deals early in the development process in order to generate revenue to support the business. The Group's lead asset is targeted towards IPF, a disease area where there is good precedent for licensing deals at early stages of development. Without licensing revenue, reliance falls on raising funds from investors or potential M&A opportunities. Failure to generate additional funding from these sources, if required, would compromise the Group's ability to achieve its strategic objectives as set out in the outlook on page 6. There is a material uncertainty around achieving early licensing deals and, if needed, raising additional funds. However, it is the Directors' reasonable expectation that the Group has adequate resources to continue to operate as a going concern for at least twelve months from the date of the approval of the accounts. In forming this assessment, the Directors have prepared cash?ow forecasts covering the period ending 31 December 2024 that take into account the likely run rate on overheads and research and development expenditure and the prudent expectations of income from out-licensing rights to its programmes or a fundraising.
The proceeds from the Lanstead sharing agreements ended in October 2023
¬∑
Feasibility of drug candidates
Pharmaceutical R&D is an inherently risky activity and drug candidates can fail due to a lack of ef?cacy, lack of potency, unsuitable pharmacokinetic properties, unacceptable toxicology profile, poor stability of the drug or formulation, poor performance of the drug product, or other technical issues unforeseen at the time of candidate selection. This is the main reason that conventional pharmaceutical R&D takes many years and billions of dollars to progress a drug from discovery through to an approved medicine. It is possible that the drug candidates selected by the Group are found to be non- viable for further development although the Group's model of repurposing and working on known drugs allows us to mitigate this risk to a certain extent.
¬∑
Failure to generate and protect our IP
If our IP rights are not adequately secured or defended against infringement, or conversely become subject to infringement claims by others, commercial exploitation could be completely inhibited. The Group constantly monitors its patents and is prepared to defend them rigorously.
By virtue of conducting research on known drugs, competitors may file patent applications on the same drugs as the Group, and thus there is a risk of securing new granted patents. There is a delay of up to 18 months in publishing patent applications and thus it is not always known whether the Group's inventions will be novel. This is mitigated through knowledge and expertise in identifying new IP and promptly filing patent applications.
¬∑
Unrealistic goals and timeframes
The Board has a duty to maintain a realistic view of the chances of success of products, deals and partnerships. Should this not be managed accurately and appropriately, the Group and its Board and staff risk ?nancial, business and reputational damage, whilst its shareholders become exposed to investment risk and uncertainty over the Group's viability and status. The Board continually reviews expectations and communications in the public domain to reduce the risk of misalignment.
¬∑
Reliance on partners
To progress the development of a drug candidate requires resources, ?nancial and otherwise, that are not necessarily available to the Group. The drug candidates that the Group wishes to develop may be of interest to third parties capable of providing these resources, so a partnership (e.g., a co-development partnership) may provide mutual bene?ts and mitigate risks for the Group. However, the speci?c strategic focus of a partner may not align totally with the Group's objectives. Maintaining a balance in a partnership is therefore a risk, such as timing, cost sharing, development decisions. Currently the Group is progressing two of its three pipeline assets without external co-development partners and thus this risk is currently minimised.
Operational risks
¬∑
Management, employees, consultants and contractors
With a fully virtual Group operating model with a reliance on consultants and contractors, the Group's ability to manage day to day tasks and its relationships with its customers and suppliers could be undermined by failure to recruit key personnel. The Group endeavours to offer attractive remuneration and a positive working environment for all people involved in its projects. The Board are incentivised as detailed in the Directors' Remuneration Report.
¬∑
Business development risks in terms of timing and success of deal ?ow
Opportunities to generate value from the portfolio have increased, but there is a need to generate further data to make the assets as attractive as possible to potential licensees. The Group seeks to extract value from its existing pipeline through early licensing deals once sufficient data are generated, to provide revenue. Generation of more robust data packages will lead to a greater probability of successful licensing discussions.
¬∑
Adapting to the external environment
The ability of the Group to quickly adapt to external events such as a pandemic may impact the delivery of our strategy. The pandemic could cause further impact to external research. Our primary focus remains the safety of our employees. The Group follows Government advice whilst allowing employees to work ?exibly. The risks are also minimised by the Group's virtual business model, allowing the Board to work remotely and effectively. Close liaison with contractors ensures that Group projects are progressed according to agreed timelines and costs.
Financial risk management
¬∑
Failure to achieve strategic plans or meet targets or expectations
The Group actively and regularly reviews and manages its capital structure to ensure an optimal capital structure and equity holder returns, taking into consideration the future capital requirements of the Group and capital ef?ciency, prevailing and projected pro?tability, projected operating cash ?ows, projected capital expenditures and projected strategic investment opportunities. Further detail on the Group's risk management policies and procedures are set out in Note 18 of the ?nancial statements.
Financial Highlights
¬∑
Net assets at year-end (18 months) of ¬£4,195,033 (2022: ¬£4,737,962) which includes ¬£202,548 cash at bank (2022: ¬£464,095)
¬∑
The Group delivered a loss on ordinary activities (after tax credit) for the 18 months of ¬£859,467 (2022: loss of ¬£1,108,993) and a loss per share of 0.12p (2022: 0.19p). The reported loss is driven mainly by costs related to the further development of pipeline assets
Future outlook
The Non-Executive Directors' Statement above gives information on the outlook of the Group.
Performance
The following are the key performance indicators ("KPIs") considered by the Board in assessing the Group's performance against its objectives. These KPIs are:
Financial KPIs
The Group is currently at a stage where the Board considers availability of cash to fund the planned R&D activities to be the primary KPI. At 30 September 2023 cash balances totalled ¬£202,548 (2022: ¬£464,095). The Board will consider introducing additional KPIs to monitor the Group's development as they become relevant in the future.
¬∑
Meeting ?nancial targets:
The Group actively and regularly reviews and manages its capital structure to ensure an optimal capital structure and equity holder returns, taking into consideration the future capital requirements of the Group and capital ef?ciency, prevailing and projected pro?tability, projected operating cash ?ows, projected capital expenditures and projected strategic investment opportunities. Further detail on the Group's risk management policies and procedures are set out in Note 18 of the ?nancial statements.
¬∑
Revenue from agreements:
During the period of these accounts, the revised Oxilio agreement has provided Nuformix with
new immediate and near-term undisclosed milestone payments
.
Non-Financial KPIs
¬∑
Progress of Lead Programmes:
The Group strategy is to generate revenue streams through applying and further developing its IP to produce proprietary product opportunities for short-term development and early out-licensing opportunities. Thus, progression of its assets towards licensing is crucial to the business.
NXP002: During the period of these accounts the Group continued to prioritise the development of NXP002, its inhaled candidate for the treatment for IPF, and generated further preclinical data.
The Group
firstly initiated further preclinical studies confirming preclinical tolerability across a new range of higher doses than previously studied following inhalation of a new nebulised formulation. In response to intelligence gathered following the attendance of key conferences, the Group switched its research focus onto further investigations of NXP002 in combination with current IPF standards of care (SoC) and demonstration of NXP002's duration of action.
This was achieved via new studies in 3D human lung tissue, firstly using a disease and species relevant IPF model, focusing on NXP002 in combination with current SoC.
Advancements within this model were designed to significantly reduce output variability. The results continued to confirm
that
NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events and that
NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis. Furthermore, both high and low concentrations of NXP002 show an additive anti-fibrotic effect to SoC. In particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis and inflammation biomarker release, yet at lower concentrations than have been seen in other preclinical models to date.
The results indicated that the clear, pronounced additive benefit of NXP002 on top of SoCs observed offers the potential for additional IPF treatment efficacy, even in patients responding to SoC therapy. The results also raised the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic response.
Lastly, the Group initiated work using an exploratory healthy human lung tissue model to investigate NXP002's duration of action. Demonstration of a prolonged duration of action is essential in the development of inhaled therapies, whose clearance from the lung can be rapid. Therapies requiring multiple (more than two) daily uses of inhalation devices for effective treatment are less attractive and suffer reduced patient compliance, even in life-threatening conditions such as IPF. Therefore,¬†Nuformix¬†has developed a TPP that is consistent with twice daily inhalation administration.
The exploratory model involves an LPS challenge to healthy human lung tissue, offering numerous advantages in terms of species relevance and the ability to control tissue exposure to drug. The model also bridges the Company's previous successful preclinical work across a variety of LPS-challenge studies.
It was found that
NXP002 suppresses the release of inflammatory cytokines by healthy human lung tissue following LPS challenge.
This effect was seen at one hour post treatment with NXP002, suggesting only a short time is required for lung tissue penetration and activity. In addition, a strong anti-inflammatory effect remained at 12 hours post drug dosing demonstrated by suppression of the release of inflammatory cytokines following
LPS challenge, confirming NXP002 has a suitable duration of action. Lastly, results indicated that anti-inflammatory effect was still observed at 24 hours post removal of drug.
Overall, the combined data generated gives the Group confidence in NXP002's potential as an inhaled therapy for IPF treatment and allows the telling of a more complete preclinical story to potential licensing partners for the first time. The Group continues to pursue opportunities to share this important new data with key players in the rare disease and respiratory disease sectors as it explore all opportunities to progress the NXP002 programme.
NXP001:
On 18 September 2023, the Company announced Oxilio had acquired
ownership of its NXP001 patent estate
for which
Nuformix
received new immediate and near-term undisclosed milestone payments
, whilst retaining further development milestones and royalties capped at¬†¬£2 million¬†per year.
NXP004: During the period of these accounts, the Group continued to perform preclinical studies investigating
the enhanced performance of NXP004 cocrystals compared to various forms of olaparib. Pre-formulation studies were first completed confirming the superiority of the Group's recently patented cocrystal forms, allowing lead cocrystals to be identified and progressed to further drug product development studies.
The Group initiated
in-vitro
dissolution performance studies for its lead cocrystals compared to the marketed Lynparza
¬Æ
tablet product using a biologically relevant dissolution design and with drug loading relevant to human dosing.
The results demonstrated that the two lead NXP004 cocrystals selected out-perform Lynparza
¬Æ
, both in terms of rate and extent of dissolution and release of olaparib.
Enhancement of dissolution in the currently marketed formulation of Lynparza
¬Æ
resulted in improved bioavailability versus the initial marketed product. Therefore, the NXP004 programme may offer potential to further increase olaparib bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.
These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products.
The Company has commenced discussions with
potential commercialisation partners.
Co-development with third parties:
Co-development of generic products with third parties, where Nuformix's knowhow or IP could provide extended patent protection is a potential business model although the Group is prioritising its resources on progressing its own portfolio to generate licensing revenue.
Section 172
The Board considers the interests of the Group's employees and other stakeholders, including the impact of its activities on the community, environment and the Group's reputation, when making decisions. The Board ensures that its decisions offer the best chance to promote the success of the Group as a whole and consider the likely and long-term consequences for all stakeholders, particularly (though not exclusively) considering the following:
¬∑
How the views and interests of all stakeholders were represented in the boardroom during the period of these accounts. Open and honest discussion at Board level considers the impact on the Group's stakeholders when reviewing items ?owing to the Board as part of its activities, whether this is reviewing strategy, budget or a business development opportunity.
¬∑
Given the size and stage of development of the Group, the Board has not formally adopted a mechanism to obtain stakeholder feedback. However, the Group's Directors can be contacted at info@nuformix.com should any stakeholders wish to contact the Group and shareholders may contact the Company's investor relations adviser, IFC Advisory Limited, at nuformix@investor-focus.co.uk.
¬∑
The Group's strategy and business model detailed in the Non-Executive Directors' Statement above.
¬∑
How the Group manages risks, on pages 9 to 15 of the Annual Report.
¬∑
Corporate governance, on pages 17 to 22 of the Annual Report, including how governance supported the delivery of our strategic objectives in this period.
Carbon Reporting
The Group has opted not to include any Streamlined Energy and Carbon Reporting (SECR) within this report as it does not meet the Large Company threshold or energy consumption threshold requiring additional reporting.
Statement of Directors' Responsibilities
The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations. Company law requires the Directors to prepare financial statements for each financial year. The Directors are required by law to prepare the Group and Parent Company financial statements in accordance with UK-adopted international accounting standards. Under Company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and Group and of the profit or loss for that period. In preparing the Company and Group's financial statements, Companies Act 2006 requires that Directors:
¬∑
Select suitable accounting policies and apply them consistently;
¬∑
Make judgements and accounting estimates that are reasonable and prudent;
¬∑
State whether applicable under UK-adopted international accounting standards, have been followed, subject to any material departures disclosed and explained in the ?nancial statements; and
¬∑
Prepare the ?nancial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.
The Directors are responsible for keeping adequate accounting records that are suf?cient to show and explain the Group transactions and disclose with reasonable accuracy at any time the ?nancial position of the Group and enable them to ensure that the ?nancial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
In the case of each person who was a director at the time of this report was approved:
¬∑
So far as that Director is aware, there is no relevant audit information of which the Group's auditor is unaware; and
¬∑
That Director has taken all steps that the director ought to have taken as a director to make himself aware of any relevant audit information and to establish that the Group's auditor is aware of that information.
Auditors
Kreston Reeves LLP were appointed as auditors in the period, and a resolution to reappoint Kreston Reeves LLP as auditors will be presented to the members at the Annual General Meeting in accordance with Section 485(2) of the Companies Act 2006.
On behalf of the board,
Dr Julian Gilbert Madeleine Kennedy
Non-Executive Director Non-Executive Director
2 January 2024
2 January 2024
Independent Auditor's Report
to the Shareholders of Nuformix plc
For the period ended 30 September 2023
Opinion
We have audited the financial statements of Nuformix PLC (the 'parent company') and its subsidiaries (the 'Group') for the year ended 30 September 2023 which comprise the consolidated income statement, consolidated statement of comprehensive income, consolidated and company statements of financial position, consolidated and company statements of changes in equity, consolidated statements of cashflow and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the United Kingdom in accordance with the provisions of the Companies Act 2006.
In our opinion, the financial statements:
¬∑
give a true and fair view of the state of the Group's and of the parent company's affairs as at 30 September 2023 and of the Group's loss for the year then ended;
¬∑
have been properly prepared in accordance with IFRSs adopted by the United Kingdom; and
¬∑
have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard as applied to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Material uncertainty relating to going concern
We draw attention to note 2 in the financial statements, which indicates that there is a significant material uncertainty in relation to the going concern status of the group.
Nuformix is a pharmaceutical development company that has undertaken significant research into targeting the pharmaceutical product gap needs in fibrosis and oncology via drug repurposing. In order to complete this work, the company will need to expend significant, and currently unquantifiable, amounts that will be in excess of the cash held at the balance sheet date of ¬£203k (2022: ¬£464k).
Given the stage in the business life cycle the Group is incurring significant losses at present, totalling to ¬£859k in the 18-month period ended 30 September 2023 (2022: year ended loss of ¬£1,109k) resulting in the group's accumulated losses at the balance sheet date of ¬£8,209k (2022: accumulated losses of ¬£7,350k). These losses are attributable to the ongoing drug research programme which is yet to reach commercial production stage where revenue could potentially be generated. The Group is therefore not in a position to self-finance and will require additional external funding which, at the date of this audit report, is unknown in quantum and not secured. Additionally, the ultimate likelihood of the development work being undertaken resulting in an effective product that is commercially viable is also unknown at this stage.
As a result of the material uncertainty with respect to going concern, we have completed the following audit work as part of our evaluation of going concern:
¬∑
Overheads and debt costs assumptions - we considered projected overheads for the 2023/24 and 2024/25 periods to ensure that these were reasonable after considering both the current and expected future profile of the business moving forward. As part of this future profiling, the non-executive directors have elected not to take payment of their salaries until such time as the business holds sufficient funds to enable them to do so.
¬∑
Credit / cash control management assumptions - we identified within the forecasting the most significant cash inflows and ensured that the valuation and timing of these were reasonable.
¬∑
We performed sensitivity analysis to assess the level of working capital headroom should key assumptions be less favourable than assumed in management's model.
¬∑
We considered post year end performance data available, including the group's future commitments, to gain additional assurance over the effectiveness of management's plans to ensure the Company and Group remain a going concern.
Based on the work we have performed we have gained sufficient assurance in order to rely on management's forecasting in forming our assessment. We have also gained assurance over the credibility of management's budgeting strategy over the next 12 months.. This included gaining assurance over the adequacy of working capital available in order to settle external liabilities as they fall due. With respect to further funding of development we have reviewed the director's assessment that they can raise the funding required in the near-term through future share capital raises.
However, whilst we have evaluated future cash inflows as reasonable for meeting current working capital needs, there is significant uncertainty surrounding the ultimate quantum and timing of funding required to reach the production stage and indeed the likelihood this stage will ever be reached. Should all or part of this funding not be received or one or both of their core projects NXP002 and NXP004 not succeed the valuation of the group's goodwill ¬£4,023,484 (2022: ¬£4,023,484), the parent company's valuation of the subsidiary investment ¬£4,023,484 (2022: ¬£4,023,484), the group's carrying value of other intangible assets ¬£57,793 (2022: ¬£126,927) and ultimately the going concern assessment of the Group would be adversely affected.
Management will continue to reduce non-essential costs in the 2024 financial period and has signed an agreement to sell the ownership of the NXP001 patent estate, which allows them to focus on NXP002 and NXP004. As part of this agreement two milestone payments have been achieved and received in the bank since the year end. However, there are further larger milestone payments due, which are unlikely to be received into the bank in the foreseeable future.
The above indicates that a significant material uncertainty exists with respect to going concern. However, as we have obtained sufficient assurance over the availability of financial resources to settle liabilities as they fall due over a period of at least the next 12 months, our opinion is not modified in respect of this matter.
An overview of the scope of our audit
As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements. In particular, we looked at where the directors made subjective judgements, for example in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits we also addressed the risk of management override of internal controls, including evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.
Group revenue
Group profit/(loss) before tax
Group net assets
Full statutory audit (Kreston Reeves)
100%
100%
100%
Limited procedures
0
0
0
Totals at 30 September 2023:
100%
100%
100%
We tailored the scope of our audit to ensure that we performed sufficient work to be able to give an opinion on the financial statements as a whole, taking into account the structure of the Group and the parent company, the accounting processes and controls, and the industry in which they operate.
Our scoping considerations for the Group audit were based both on financial information and risk. As noted above limited assurance audit work - which is to say the audit of balances and transactions material at a group level - was not utilised due to statutory audit requirements of all group entities. The below table summarises for the parent company and its subsidiaries, the level of assurance gained:
Group component
Level of assurance
Nuformix PLC
Full statutory audit (Kreston Reeves LLP)
Nuformix Technologies Limited
Full statutory audit (Kreston Reeves LLP)
Key audit matters
Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) we identified, including those which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit; and directing the efforts of the engagement team.
These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. This is not a complete list of all risks identified by our audit.
Impairment
of goodwill / Valuation of investment:
Significance and nature of key risk
The Group has significant goodwill generated from an investment in subsidiary of ¬£4,023,484. In addition, the parent company holds an equal investment value of ¬£4,023,484 on it's company balance sheet relating to the same subsidiary.
We identified there was a risk in relation to the impairment on the goodwill / investment held with regards to the trading subsidiary.
Management's assessment of the recoverable amount of investment in a subsidiary requires estimation and judgement around assumptions used, including the cash flows to be generated from the continuing operations of the subsidiary. Changes to assumptions could lead to material changes in the estimated recoverable amount, impacting the value of investment in the subsidiary and impairment charges.
For the purpose of assessing impairment on goodwill arising from business combination, goodwill is allocated to a single cash generating units ('CGU') and the recoverable amount of the CGU was determined with reference to value-in-use (the 'VIU') calculations using cash flow projections. In carrying out the impairment assessment, significant management judgement was used to determine the key assumptions underlying the VIU calculations.
We have identified the above matter as a key audit matter because goodwill is material to the Group and the valuation of the investment is material to the parent company. The estimation of recoverable amount of the CGU involved a significant degree of management judgement and therefore was subject to an inherent risk of error.
How our audit addressed the key risk
During the course of the audit, we undertook the following key procedures:
¬∑
assessing the appropriateness of the VIU calculations used by the management to estimate recoverable amount of CGU;
¬∑
reconciling key input data applied in the VIU calculations to reliable supporting evidence; and
¬∑
challenging the reasonableness of key assumptions based on our knowledge and understanding of the business and industry.
¬∑
Reviewed management's plan of future operating cashflows of the subsidiary; and
¬∑
obtaining evidence of the commercial and technical feasibility of the patents owned by the subsidiary.
There were also other procedures which are not deemed to be key and have therefore not been listed above.
Based on the audit work performed, we are satisfied with management's valuation of goodwill and investment as featured within these financial statements.
Key observations communicated to the Audit & Risk Committee
We have no significant concerns over the material accuracy of valuation / impairment of investment values recognised in the financial statements.
Our application of materiality
Group financial statements
Parent company financial statements
Overall Materiality
¬£98,100
¬£95,300
How we determined it
2% of Group gross assets
2% of Company gross assets
Rationale for benchmark
The group is focused on the development of its Intellectual Property (IP) and the assets held in order to finance the continuing development of this IP. As such, the most appropriate basis for the group financial statements is gross assets.
The parent company is principally holding subsidiary investment. The users of the financial statements will be most concerned with the value of investment. As such, the most appropriate basis for the parent company materiality is gross assets.
We reported all audit differences found in excess of our triviality threshold of ¬£4,900 to the directors and the management board as well as misstatements below those amounts that, in our view, warranted reporting for qualitative reasons.
Other information
The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
¬∑
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
¬∑
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of our knowledge and understanding of the Group and parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
¬∑
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
¬∑
the parent company financial statements are not in agreement with the accounting records and returns; or
¬∑
certain disclosures of directors' remuneration specified by law are not made; or
¬∑
we have not received all the information and explanations we require for our audit
Responsibilities of directors
As explained more fully in the directors' responsibilities statement (set out on pages 29 and 30), the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the Group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.
Based on our understanding
o
f the
group
and industr
y
, and through discussion
wit
h the directors and other
m
anage
m
ent
(a
s required by a
uditin
g standards),
w
e identified that the principal
risk
s
o
f non-compliance
with law
s and regulations related to health and
safet
y
, anti-bribery and e
m
plo
y
m
ent
law
.
W
e
considere
d
th
e
exten
t
to
whic
h non-compliance
m
i
ght
hav
e a
m
aterial
effec
t on the financial statements.
W
e also considered those
laws
and regulations that
hav
e a direct
i
m
pact on the preparation
o
f the financial statements such as the Companies Act 2006, taxation and pension legislation.
W
e
c
o
mm
unicated identified
law
s and regulations throughout our
tea
m
and
remained
alert
to
any
i
ndications
o
f
non-compliance throughout
the
audit.
We evaluated
m
anage
m
ent's incentives and opportunities
fo
r fraudulent
m
a
nipulatio
n
o
f the financial statements (including the
ris
k
o
f override
o
f controls) and determined that the principal
risk
s
wer
e related to posting inappropriate journal entries to increase revenue or reduce expenditure and
m
anage
m
ent bias
i
n accounting estimates and
judgementa
l
area
s
o
f
th
e
financia
l
statement
s
suc
h
a
s
th
e
valuatio
n
o
f
intangible assets and investments
.
Audi
t
procedure
s
performe
d
b
y
the group
engage
m
ent team included:
¬∑
Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations and fraud, and review of the reports made by
m
anage
m
ent; and
¬∑
Assessment of identified fraud risk factors; and
¬∑
Challenging assumptions and judgements made by management in its significant accounting estimates; and
¬∑
Performing integrity testing to verify the legitimacy of banking records obtained from management; and
¬∑
Performing anal
y
tical procedures to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
¬∑
Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and
¬∑
Performing analytical procedures with automated data analytics tools to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
¬∑
Reading minutes of meetings of those charged with governance, reviewing internal audit reports and reviewing correspondence with relevant tax and regulatory authorities; and
¬∑
Review of significant and unusual transactions and evaluation of the underl
y
ing financial rationale supporting the transactions.
There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
¬∑
Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
¬∑
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
¬∑
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
¬∑
Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's or the parent company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group or the parent company to cease to continue as a going concern.
¬∑
Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
¬∑
Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
Use of our Report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Anne Dwyer BSc(Hons) FCA (Senior Statutory Auditor)
For and on behalf of
Kreston Reeves LLP
Chartered Accountants
Statutory Auditor
London
Date: 2 January 2024
Consolidated Statement of Comprehensive Income
for the Period Ended 30 September 2023
Note
Period ended
30 September
2023
¬£
Year ended
31 March
2022
¬£
Revenue
3
-
50,000
Cost of sales
-
(1,695)
Gross pro?t
-
48,305
Administrative expenses
(927,972)
(1,318,577)
Operating loss
4
(927,972)
(1,270,272)
Loss before tax
(927,972)
(1,270,272)
Income tax credit
8
68,505
161,279
Loss for the year and total comprehensive loss for the year
(859,467)
(1,108,993)
Loss per share - basic and diluted
9
(0.12)p
(0.19)p
The above results were derived from continuing operations.
The accompanying notes to the ?nancial statements form an integral part of the ?nancial statements.
Consolidated Statement of Financial Position
As at 30 September 2023
Registration number: 09632100
Note
30 September
2023
¬£
31 March
2022
¬£
Assets
Non-current assets
Property, plant and equipment
10
-
438
Intangible assets
11
4,081,277
4,150,411
4,081,277
4,150,849
Current assets
Trade and other receivables
12
66,857
199,600
Income tax asset
67,342
161,279
Cash and cash equivalents
13
202,548
464,095
336,747
824,974
Total assets
4,418,024
4,975,823
Equity and liabilities
Equity
Share capital
14
744,309
615,609
Share premium
6,656,802
6,500,817
Merger relief reserve
10,950,000
10,950,000
Reverse acquisition reserve
(8,005,195)
(8,005,195)
Share option reserve
2,058,518
2,026,664
Retained earnings
(8,209,400)
(7,349,933)
Total equity
4,195,034
4,737,962
Current liabilities
Trade and other payables
17
222,990
237,861
222,990
237,861
Total equity and liabilities
4,418,024
4,975,823
These ?nancial statements were approved by the board on 2 January 2024 and signed on its behalf by:
Madeleine Kennedy
Director
The accompanying notes to the ?nancial statements form an integral part of the ?nancial statements.
Consolidated Statement of Changes in Equity
for the Period Ended 30 September 2023
Share capital
¬£
Share premium
¬£
Merger relief reserve
¬£
Reverse acquisition
reserve
¬£
Share option reserve
¬£
Retained earnings
¬£
Total
¬£
At 1 April 2022
615,609
6,500,817
10,950,000
(8,005,195)
2,026,664
(7,349,933)
4,737,962
Loss for the year and total comprehensive loss
-
-
-
-
-
(859,467)
(859,467)
Issue of share capital
128,700
160,285
-
-
-
-
288,985
Share issue costs
-
(4,300)
-
-
-
-
(4,300)
Share and warrant based payment
-
-
-
-
31,854
-
31,854
At 30 September 2023
744,309
6,656,802
10,950,000
(8,005,195)
2,058,518
(8,209,400)
4,195,034
Share capital
¬£
Share premium
¬£
Merger relief reserve
¬£
Reverse
acquisition
reserve
¬£
Share option reserve
¬£
Retained
earnings
¬£
Total
¬£
At 1 April 2021
591,609
6,384,835
10,950,000
(8,005,195)
2,005,952
(6,240,940)
5,686,261
Loss for the year and total comprehensive loss
-
-
-
-
-
(1,108,993)
(1,108,993)
Issue of share capital
24,000
145,982
-
-
-
-
169,982
Share issue costs
-
(30,000)
-
-
-
-
(30,000)
Share and warrant based payment
-
-
-
-
20,712
-
20,712
At 31 March 2022
615,609
6,500,817
10,950,000
(8,005,195)
2,026,664
(7,349,933)
4,737,962
The accompanying notes to the ?nancial statements form an integral part of the ?nancial statements.
Consolidated Statement of Cash Flows
for the Period Ended 30 September 2023
Note
30 September
2023
¬£
31 March
2022
¬£
Cash ?ows from operating activities
Loss for the year
(859,467)
(1,108,993)
Adjustments to cash ?ows from non-cash items
Profit on Sale of intangibles
(35,552)
-
Depreciation and amortisation
10,11
55,124
36,976
Income tax credit
8
(68,505)
(161,279)
Share and warrant based payment
31,854
20,712
(876,546)
(1,212,584)
Working capital adjustments
(Increase)/Decrease in trade and other receivables
12
132,743
(167,340)
(Decrease)/Increase in trade and other payables
17
(14,870)
(86,763)
Cash consumed by operations
(708,674)
(1,466,687)
Income taxes received
162,442
121,020
Net cash used in operating activities
(546,232)
(1,345,667)
Cash ?ows from investing activities
Proceeds from sale of intangibles
50,000
-
Net cash from investing activities
50,000
-
Cash ?ows from ?nancing activities
Issue of shares (net of costs)
284,685
139,982
Net cash from ?nancing activities
284,685
139,982
Net increase/(decrease) in cash and cash equivalents
(261,547)
(1,205,685)
Cash and cash equivalents at 1 April 2022
464,095
1,669,780
Cash and cash equivalents at 30 September 2023
202,548
464,095
T
he accompanying notes to the ?nancial statements
form
an integral part of the ?nancial
statements
Notes to the Consolidated Financial Statements
for the Period Ended 30 September 2023
1. General information
Nuformix plc ("the Company") and its subsidiary (together, "the Group") operate in the ?eld of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing.
The Company is a public limited company which is listed on the Standard List of the London Stock Exchange, domiciled in the United Kingdom ("the UK") and incorporated in England and Wales.
The address of its registered of?ce is 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
The company operates in a virtual manner and as such does not have a principal place of business.
The company extended its accounting period from 31 March 2023 to 30 September 2023 to allow sufficient time to appoint new auditors. Due to this change the current year figures included in the statement of comprehensive income, statement of cash flows and related notes represent 18 months of transactions in comparison to the 12 months represented in the previous period by the comparative.
2. Summary of Significant Accounting policies
Basis of preparation
Nuformix plc transitioned to UK-adopted International Accounting Standards in its Group and Parent Company financial statements on 1 April 2021. This change constitutes a change in accounting framework. However, there is no change on recognition, measurement or disclosure in the financial year reported as a result of the change in framework.
These Group and Parent Company financial statements were prepared in accordance with UK-adopted International Accounting Standards and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards.
The financial statements of the Group and Parent Company have been prepared on accrual basis and under historical cost convention. The ?nancial statements are presented in Pounds Sterling which is the Group's functional and presentational currency.
New Standards and Interpretations
No new standards, amendments or interpretations, effective for the first time for the period beginning on or after 1 April 2022 have had a material impact on the Group.
Standards, amendments and interpretations that are not yet effective and have not been early adopted are as follows:
Standard
Impact on initial application
Effective date
IAS 1
Classification of liabilities as current or non-current
Not earlier than 1 January 2024
IAS 1
Disclosure of accounting policies
1 January 2023
IAS 8
Accounting estimates
1 January 2023
IAS 12
IFRS 7
IFRS 16
Deferred tax related to assets and liabilities arising from a single transaction
Supplier finance
Leases on sale and leaseback
1 January 2023
1 January 2024
1 January 2024
IFRS 17
IAS 21
Insurance contracts
Lack of exchangeability
1 January 2023
1 January 2025
The Directors are evaluating the impact of the new and amended standards above. The Directors believe that these new and amended standards are not expected to have a material impact on the financial statements of the Group
Going concern
The ?nancial statements have been prepared on the going concern basis of preparation which, inter alia, is based on the Directors' reasonable expectation that the Group and Parent Company has adequate resources to continue to operate as a going concern for at least twelve months from the date of approval of these financial statements. In forming this assessment, the Directors have prepared cash?ow forecasts covering the period ending 31 December 2024 that take into account the likely run rate on overheads and research and development expenditure and the estimates of the possibilities of raising funds through issues of equity and have considered alternative strategies should projected income be delayed or fail to materialise.
The Group is not in a position for self-financing and will require further funding which has not yet been secured. Whilst the Directors understand the risks and issues around raising further funds through an equity raise, this will be carefully considered, as and when appropriate.
These circumstances indicate the existence of an inherent material uncertainty which may cast a significant doubt on the Group's and Parent Company's ability to continue as a going concern, when in twelve - eighteen months' time a thorough review of funding will be required. However, these scenarios have already been considered and will continue to be closely monitored by the Directors. The ?nancial statements do not include any adjustments that would result if the company or Group was unable to continue as a going concern.
The Directors have carried out a thorough review of costs and are clear on the development work to be completed. Discretionary costs have been carefully reviewed and reduced where reasonable to do so while continuing to allow the prudent running of the business. In addition, the non-executive directors have elected not to take payment of their salaries until such time as the business holds sufficient funds to enable them to do so.
After careful consideration, the Directors consider that they have reasonable grounds to believe that the Group can be regarded as a going concern and for this reason they continue to adopt the going concern basis in preparing the Group's ?nancial statements.
Critical Accounting Estimates and Judgements
The preparation of these ?nancial statements under UK-adopted International Accounting Standards requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the ?nancial statements and the reported amounts of revenues and expenses during the reporting year. These estimates and assumptions are based upon management's knowledge and experience of the amounts, events or actions. Actual results may differ from such estimates.
The critical accounting estimates are considered to relate to the following:
i) Intangible assets
The Group recognises intangible assets in respect of goodwill arising on consolidation. This recognition requires the use of estimates, judgements and assumptions in determining whether the goodwill is impaired at each year end, using a NPV calculation assuming a 20% discount rate.
ii) Share options
The Group's fair values equity-settled share-based payment transactions using the Black-Scholes model. The use of the models involves judgements and estimates including an assessment of whether the shares will vest. Should actual future outcomes differ from these assessments the amounts recognised on a straight-line basis would vary from those currently recognised. The total charge in the period to 30 September 2023 was ¬£31,854.
iii) Basis of consolidation
The Group's financial statements consolidate those of the parent company and its subsidiary as of 30 September 2023. Its subsidiary has a reporting date of 30 September.
All transactions and balances between Group companies are eliminated on consolidation, including unrealised gains and losses on transactions between Group companies. Where unrealised losses on intra-group asset sales are reversed on consolidation, the underlying asset is also tested for impairment from a Group perspective. Amounts reported in the financial statements of its subsidiary have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group.
Profit or loss and other comprehensive income of subsidiaries acquired or disposed of during the year are recognised from the effective date of acquisition, or up to the effective date of disposal, as applicable.
iv) Business combinations
The Group applies the acquisition method in accounting for business combinations. The consideration transferred by the Group to obtain control of a subsidiary is calculated as the sum of the acquisition-date fair values of assets transferred, liabilities incurred and the equity interests issued by the Group, which includes the fair value of any asset or liability arising from a contingent consideration arrangement. Acquisition costs are expensed as incurred. Assets acquired and liabilities assumed are generally measured at their acquisition-date fair values.
v) Revenue recognition
Revenue comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the Group's activities. Revenue is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the Group.
The Group recognises revenue when:
?
the amount of revenue can be reliably measured;
?
it is probable that future economic bene?ts will ?ow to the entity; and,
?
speci?c criteria have been met for each of the Group activities, such as the demonstration of milestone achievements in research or acceptance by both parties.
After applying the above criteria, no revenue was recognised in the Income Statement in the period.
Segmental information
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-makers. The chief operating decision-makers, who are responsible for allocating resources and assessing performance of the operating segments, has been identified as the executive Board of Directors.
All operations and information are reviewed together so that at present there is only one reportable operating segment.
In the opinion of the Directors, during the year the Group operated in the single business segment of the research and development of pharmaceutical products using technology developed by the Group.
Taxation
Taxation comprises current and deferred tax. Current tax is based on taxable profit or loss for the period. Taxable pro?t differs from net pro?t or loss as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Group's current tax asset is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date.
Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial information and the corresponding tax bases used in the computation of taxable profit and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from initial recognition of goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.
Deferred tax liabilities are recognised for taxable temporary differences arising on investments in subsidiaries and associates, and interests in joint ventures, except where the Company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.
The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled, or the asset realised. Deferred tax is charged or credited to profit or loss, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity.
Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.
Property, plant and equipment
Property, plant and equipment is stated in the statement of ?nancial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of property, plant and equipment includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged to write off the cost of assets over their estimated useful lives, as follows:
Asset class
Depreciation method and rate
Computer equipment
33.33% straight line
Goodwill and Intangible assets
Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the Group's interest in the net fair value of the identi?able assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less any accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting year date.
Goodwill is not amortised, but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold.
Goodwill is allocated to cash-generating units ("CGUs") for the purpose of impairment testing. The allocation is made to those CGUs or groups of CGUs that are expected to bene?t from the business combination in which the goodwill arose. The Group currently has only one CGU.
Other intangible assets, including customer relationships, licences, patents and trademarks, that are acquired by the Group and have finite useful lives are measured at cost less accumulated amortisation and any accumulated impairment losses.
Amortisation is provided on the Group's patents to write off the cost, less any estimated residual value, over their expected useful economic life on a 10% straight line basis.
Impairment testing of goodwill, other intangible assets and property, plant and equipment
For impairment assessment purposes, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). As a result, some assets are tested individually for impairment and some are tested at cash-generating unit level. Goodwill is allocated to those cash-generating units that are expected to benefit from synergies of a related business combination and represent the lowest level within the Group at which management monitors goodwill.
Cash-generating units to which goodwill has been allocated (determined by the Group's management as equivalent to its operating segments) are tested for impairment at least annually. All other individual assets or cash-generating units are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognised for the amount by which the asset's (or cash-generating unit's) carrying amount exceeds its recoverable amount, which is the higher of fair value less costs of disposal and value-in-use. To determine the value-in-use, management estimates expected future cash flows from each cash-generating unit and determines a suitable discount rate in order to calculate the present value of those cash flows. The data used for impairment testing procedures are directly linked to the Group's latest approved budget, adjusted as necessary to exclude the effects of future reorganisations and asset enhancements. Discount factors are determined individually for each cash-generating unit and reflect current market assessments of the time value of money and asset-specific risk factors.
Impairment losses for cash-generating units reduce first the carrying amount of any goodwill allocated to that cash-generating unit. Any remaining impairment loss is charged pro rata to the other assets in the cash-generating unit.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insigni?cant risk of changes in value.
Financial instruments
IFRS 9 requires an entity to address the classification, measurement and recognition of financial assets and liabilities.
i)
Classification
The Company classifies its financial assets in the following measurement categories:
?
those to be measured at amortised cost.
The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows.
The Company classifies financial assets as at amortised cost only if both of the following criteria are met:
?
the asset is held within a business model whose objective is to collect contractual cash flows; and
?
the contractual terms give rise to cash flows that are solely payment of principal and interest.
ii) Recognition
Purchases and sales of financial assets are recognised on trade date (that is, the date on which the Company commits to purchase or sell the asset). Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership.
iii) Measurement
At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset.
Transaction costs of financial assets carried at FVPL are expensed in profit or loss.
Debt instruments
Amortised cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented as a separate line item in the statement of profit or loss.
iv) Impairment
The Company assesses, on a forward-looking basis, the expected credit losses associated with any debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the Company applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.
Financial liabilities
The Group's financial liabilities include other payables.
Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss.
Subsequently, financial liabilities are measured at amortised cost using the effective interest method except for derivatives and financial liabilities designated at FVTPL, which are carried subsequently at fair value with gains or losses recognised in profit or loss (other than derivative financial instruments that are designated and effective as hedging instruments).
All interest-related charges and, if applicable, changes in an instrument's fair value that are reported in profit or loss are included within finance costs or finance income.
Equity
Equity comprises the following:
?
"Share capital" represents the nominal value of equity shares.
?
"Share premium" represents the amount paid for equity shares over the nominal value.
?
"Reverse acquisition reserve" arises due to the elimination of the Company's investment in Nuformix Technologies Limited.
?
"Merger relief reserve" represents the share premium arising on issue of shares in respect of the reverse acquisition takeover.
?
"Share option reserve" represents the fair value of options issued.
?
"Retained earnings" represents retained earnings/losses.
De?ned contribution pension obligation
A de?ned contribution plan is a pension plan under which ?xed contributions are paid into a separate entity and has no legal or constructive obligations to pay further contributions if the fund does not hold suf?cient assets to pay all employees the bene?ts relating to employee service in the current and prior years.
For de?ned contribution plans contributions are paid into publicly or privately administered pension insurance plans on a mandatory or contractual basis. The contributions are recognised as employee bene?t expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as an asset.
Share based payments
Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. The fair value excludes the effect of non-market-based vesting conditions. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in note 17.
The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of the number of equity instruments that will eventually vest. At each reporting date, the Group revises its estimate of the number of equity instruments expected to vest as a result of the effect of non-market-based vesting conditions. The impact of the revision of the original estimates, if any, is recognised in pro?t or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to reserves.
Equity
?
settled share
?
based payment transactions with parties other than employees are measured at the fair value of the goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the service.
For cash
?
settled share
?
based payments, a liability is recognised for the goods or services acquired, measured initially at the fair value of the liability. At each reporting date until the liability is settled, and at the date of settlement, the fair value of the liability is remeasured, with any changes in fair value recognised in pro?t or loss for the year.
Earnings per Ordinary Share
The Company presents basic and diluted earnings per share data for its Ordinary Shares.
Basic earnings per Ordinary Share is calculated by dividing the profit or loss attributable to Shareholders by the weighted average number of Ordinary Shares outstanding during the period.
Diluted earnings per Ordinary Share is calculated by adjusting the earnings and number of Ordinary Shares for the effects of dilutive potential Ordinary Shares
Investment in subsidiaries
Investments in subsidiaries are carried in the Company's balance sheet at cost less accumulated impairment losses. On disposal of investments in subsidiaries the difference between disposal proceeds and the carrying amounts of the investments are recognised in pro?t or loss.
3. Revenue
The analysis of the Group's revenue for the year from continuing operations is as follows:
30 Sep 2023
¬£
31 March
2022
¬£
Licensing Fees
-
50,000
-
50,000
4. Operating loss
Arrived at after charging
30 Sep
2023
¬£
31 March
2022
¬£
Depreciation expense
438
519
Amortisation expense
54,686
36,457
Profit on disposal of intangible ?xed assets
35,552
-
Research and development expenditure
245,101
572,921
Share option and warrant charge
31,854
20,712
Details of the share-based payments can be found in
Note 15
.
5. Staff costs
The aggregate payroll costs (including directors' remuneration) were as follows:
30 Sep
2023
¬£
31 March
2022
¬£
Wages and salaries
141,833
197,983
Social security costs
7,112
18,533
Pension costs, de?ned contribution scheme
-
1,721
148,945
218,237
The average number of persons employed by the Group (including directors) during the year and analysed by category was as follows:
30 Sep
2023
No.
31 March
2022
No.
Research and development
1
3
Non-executive directors
2
2
Total
3
5
6. Directors' remuneration
The Directors' remuneration for the year was as follows:
30 Sep
2023
¬£
31 March
2022
¬£
Remuneration
141,833
197,983
Share based payment charge
19,474
3,895
161,307
201,878
Further information about the remuneration of individual directors are provided in the Directors' Remuneration Report.
During the year, the number of Directors who were receiving pension bene?ts was as follows:
30 Sep
2023
No.
31 March
2022
No.
Accruing bene?ts under money purchase pension scheme
-
2
Details of the total remuneration paid for the services of the directors are set out on
pages 23 to 27
in the Remuneration Report section of the Annual Report.
In respect of the highest paid director:
30 Sep
2023
¬£
31 March
2022
¬£
Remuneration
44,500
72,143
7.
Auditors' remuneration
30 Sep
2023
¬£
31 March
2022
¬£
Audit of the ?nancial statements - Group
37,000
34,000
Audit of the ?nancial statements - Subsidiary
18,000
19,000
8.
Income tax
Tax (credited) in the income statement
30 Sep
2023
¬£
31 March
2022
¬£
Current taxation
UK corporation tax
(67,342)
(161,279)
Adjustment in respect of prior years
(1,163)
-
(68,505)
(161,279)
The tax on loss before tax for the period is higher than (2022: lower than) the standard rate of corporation tax in
the UK of 25%
(2022: 19%).
The differences are reconciled below:
30 Sep
2023
¬£
31 Mar
2022
¬£
Loss before tax
(927,972)
(1,270,272)
Corporation tax at standard rate 19%
(176,315)
(241,352)
Excess
of
depreciation over capital allowances
3,611
6,932
Expenses not deductible
45
3,935
Tax losses for which no deferred tax asset was recognised
135,025
138,601
Adjustment in respect of research and development tax credit
(29,708)
(69,396)
Adjustment in respect of prior years
(1,163)
-
Total tax credit
(68,505)
(161,279)
No deferred tax asset has been recognised as the Directors cannot be certain that future pro?ts will be suf?cient for this asset to be realised. As at 30 September 2023 the Group has tax losses carried forward of approximately
¬£5,535,000
(2022: ¬£
4,853,000
).
8. Income Tax (cont.)
Factors that may affect future tax charges
Since 1 April 2017 there has been a single rate of corporation tax of 19% in place. From 1 April 2023, the main rate of corporation tax will rise to 25% for companies with profits over ¬£250,000. For companies with profits of ¬£50,000 or less, they will pay corporation tax at the small profits rate of 19%. Where a company's profits fall between ¬£50,000 and ¬£250,000, they will pay corporation tax at the main rate reduced by marginal relief. The upper and lower limits will be proportionally reduced for short accounting periods and where there are associated companies.
9. Loss per share
Loss
per
share
is
calculated
based
on
the
weighted
average number of shares outstanding during the period. Diluted loss per share is calculated based on the weighted average number of shares outstanding and the number of shares issuable as a result of the conversion of dilutive ?nancial instruments.
30 Sep
2023
¬£
31 March
2022
¬£
Loss after tax
(859,467)
(1,108,993)
Weighted average number of shares -
basic and diluted
719,462,470
598,447,724
Basic and diluted loss per share
(0.12)p
(0.19)p
There is no difference between the basic and diluted earnings per share as the effect would be to decrease earnings per share.
10.
Property, plant and equipment
Computer equipment
Total
¬£
¬£
Cost
At 1 April 2022
1,561
1,561
Disposals
(1,561)
(1,561)
At 30 September 2023
-
-
Depreciation
At 1 April 2022
1,123
1,123
Charge for the year
438
438
Eliminated on disposal
(1,561)
(1,561)
At 30 September 2023
-
-
Carrying amount
At 30 September 2023
-
-
At 31 March 2022
438
438
11.
Intangible assets
Goodwill
¬£
Patents
¬£
Total
¬£
Cost
At 1 April 2022
4,023,484
364,576
4,388,060
Additions
-
-
-
Disposals
-
(72,915)
(72,915)
At 30 September 2023
4,023,484
291,661
4,315,145
Amortisation
At 1 April 2022
-
237,649
237,649
Amortisation charge
-
54,686
54,686
On disposals
-
(58,467)
(58,467)
At 30 September 2023
-
233,868
233,868
Net book value
At 30 September 2023
4,023,484
57,793
4,081,277
At 31 March 2022
4,023,484
126,927
4,150,411
For impairment testing purposes, management considers the operations of the Group to represent a single
cash
generating
unit
(CGU)
focused
on
pharmaceutical development, targeting unmet medical needs in fibrosis and oncology via drug repurposing. The directors have assessed the recoverable amount of goodwill, which in accordance with IAS36 is the higher of its value in use and its fair value less cost to sell (fair value), in determining whether there is evidence of impairment.
As at 30 September 2023, the Group assessed the recoverable amount of the CGU with reference to a value-in-use calculation based on cash flow projection of the subsidiary. The calculations use cash flow projection based on financial budgets approved by the Directors covering a 30-year period with a discount rate of 20% assumed. The recoverable amount of the CGU based on the value-in-use calculation exceeded its carrying amount. The Directors also assessed the market capitalisation of the Group with reference to the share price of the Company and supported the view that goodwill is not impaired.
12.
Trade and other receivables
30
Sep
31 March
2023
¬£
2022
¬£
Prepayments
17,919
27,941
Other receivables
48,938
171,659
66,857
199,600
The fair value of trade and other receivables is considered by the Directors not to be materially different to the carrying amounts.
13.
Cash and cash equivalents
30 Sep
31 March
2023
¬£
2022
¬£
Cash at bank
202,548
464,095
The Directors consider that the carrying value of cash and cash equivalents represents their fair value.
14.
Share capital
Allotted, called up and fully paid shares
31
Sep
2023
31 March
2022
No.
¬£
No.
¬£
Ordinary shares of ¬£0.001 each
744,309,368
744,309
615,609,368
615,609
No.
As at 1 April 2022
615,609,368
Placement of new shares on the stock market
128,700,000
As at 30 September 2023
744,309,368
On
11 April 2022 and
21 April 2023, the company completed capital increases through the issue of 128,700,000 shares of ¬£0.001 each in share placements, with an overall share premium of ¬£160,285.
15. Share options and warrants
The Group operates share-based payment arrangements to remunerate Directors and key employees in the
form
of
a
share
option
scheme.
Equity-settled
share-based
payments
are
measured
at
fair
value
(excluding
the
effect of non-market based vesting conditions) at the date of grant. The fair value is determined at the grant date of the equity-settled share-based payments and is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest and adjusted for the effect of non- market based vesting conditions.
The following share-based payments were made in the year to 30 September 2023:
On
31 January 2022,
the directors, A. Riddell, J. Gilbert and M. Kennedy were
granted
warrants to subscribe for 3,000,000 new Ordinary shares
of
¬£0.001
at
an
exercise
price
of
1
.45p
each.
The
warrants
are exercisable up until November 2024.
The fair value of the warrants was determined using the Black-Scholes option pricing model at 1.45p per warrant.
The fair value of the options and warrants issued in 2022 were determined using the Black-Scholes option
pricing
model,
where
appropriate,
and
had
a
weighted
average
of
2.46p
per
option
(2022: 2.46p).
The signi?cant inputs into the model in respect of the options and warrants granted in the periods ended
31 March 2022 and 30 September 2023 were as follows:
2023
Existing director warrants
2022
Existing
director
warrants
Grant date share price
1p
1.45-4.15p
Exercise price
1.45p
1.45-2.80p
No. of share options
9,000,000
13,746,943
Risk free rate
0.153%
0.153-0.44%
Expected volatility
97%
50-97%
Expected option life
3 years
1-5 years
The following table sets out details of the granted warrants and options movements:
Warrant/ option holder
Number of warrants / options at 31 March 2021
Issued in year
Lapsed in year
Number of warrants/ options at 31 March 2022
Issued in period
Lapsed in peiod
Number of warrants/ options at 30 September 2023
Exercise price
Expiry date
Directors during year
J Holland
36,860,000
-
-
36,860,000
-
(36,860,000)
-
4-10p
16/10/2022
K Keegan
3,000,000
-
(3,000,000)
-
-
-
-
6.75p
10/05/2021
J Gilbert
-
3,000,000
-
3,000,000
-
-
3,000,000
1.45p
23/11/2024
M Kennedy
-
3,000,000
-
3,000,000
-
-
3,000,000
1.45p
23/11/2024
A Riddell
-
3,000,000
-
3,000,000
-
-
3,000,000
1.45p
23/11/2024
Previous directors
D Gooding
36,860,000
-
-
36,860,000
-
(36,860,000)
-
4-10p
16/10/2022
C Blackwell
3,000,000
-
(3,000,000)
-
-
-
-
4p
10/05/2021
Other warrants/options
Novum Securities Limited
580,357
-
-
580,357
-
-
580,357
2.8p
21/10/2025
Other warrants
580,356
-
-
580,356
-
-
580,356
2.8p
21/10/2025
Other warrants (2023)
-
-
-
-
35,000,000
-
35,000,000
0.2p
17/04/2025
Alex Eberlin
586,229
-
-
586,229
-
-
586,229
4.691p
18/12/2023
81,466,942
9,000,000
(6,000,000)
84,466,942
35,000,000
(73,720,000)
45,746,942
16. Pension and other schemes
De?ned contribution pension
sc
heme
The
Group
operates
a
de?ned
contribution
pension
scheme.
The
pension
cost
charge for the year represents
contributions payable by the Group to the scheme
. No contributions were made in the period to 30 September 2023
(2022: ¬£1,721).
No contributions were payable to the scheme
at 30 September 2023 or 31 March 2022.
17. Trade and other payables
30
Sep
31 March
2023
2022
¬£
Trade payables
69,774
12,351
Accrued expenses
152,043
218,202
Social security and other taxes
1,174
7,308
222,991
237,861
The fair value of trade and other payables is considered by the Directors not to be materially different to the carrying amounts. All payables are due within one year.
18. Financial instruments
Credit risk
The main credit risk relates to liquid funds held at banks. The credit risk in respect of these bank balances is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies.
Liquidity risk
The
Group
seeks
to
manage
?nancial
risk,
to
ensure
suf?cient
liquidity
is
available
to
meet
foreseeable
needs.
An analysis of trade and other payables is given
in note 17.
Capital risk management
The Group's objectives when managing capital are:
?
to safeguard the Group's ability to continue as a going concern, so that it continues to provide returns and bene?ts for shareholders
?
to support the Group's growth; and
?
to provide capital for the purpose of strengthening the Group's risk management capability.
The Group actively and regularly reviews and manages its capital structure to ensure an optimal capital structure and equity holder returns, taking into consideration the future capital requirements of the Group and capital ef?ciency, prevailing and projected pro?tability, projected operating cash ?ows, projected capital
expenditures
and
projected
strategic
investment
opportunities.
Management
regards
total
equity
as
capital and
reserves, for capital management purposes.
19. Related party transactions
All transactions with related parties are conducted on an arm's length basis.
The remuneration of the key management personnel of the Group, who are de?ned as the directors, is set out
in the directors' remuneration report.
20.
Ultimate controlling party
The directors do not consider there to be a single ultimate controlling party.
21. Post Balance Sheet Events
The directors do not consider that any events after the balance sheet event give rise to adjusting or non-adjusting events and therefore no adjustments or disclosure are required.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
FR EAPFAESFLEFA
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Notice of AGM</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">31st Jul 2023</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">2:00 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Investor Information</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
31 Jul 2023 14:00
RNS Number : 7165H
Nuformix PLC
31 July 2023
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Notice of
Annual General Meeting ("AGM")
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurp
osing, announces that the 2023 Notice of AGM has today been posted to its shareholders:
A full pdf version of the Notice of AGM will shortly be available for download from the Investor Information section on the Company's website
www.nuformix.com
.
The AGM will be held on 24 August 2023 at 10.00 am at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director
Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)
+44 (0) 20 3650 3650
John Howes / Bob Pountney (Corporate Broking)
+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe
Zach Cohen
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.
For more information, please visit
www.nuformix.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
NOADFLBXXDLLBBD
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-17 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>